



GLAND PHARMA LIMITED

June 15, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Outcome of Board Meeting

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"); we would like to inform you that the Board of Directors (the "**Board**") of Gland Pharma Limited (the "**Company**") at its Meeting held today, i.e. Monday, June 15, 2026, has inter-alia considered and approved:

- I. Re-appointment of Mr. Udo Johannes Vetter (DIN: 00707474) as an Independent Director of the Company for the second term of five consecutive years, with effect from July 21, 2026 till July 20, 2031.

The approval of the members as required under Regulation 17(1A) and 25(2A) of Listing Regulations for the aforesaid re-appointment will be obtained within the stipulated timelines, through a postal ballot and e-voting.

- II. Appointment of Mr. William Robert Keller (DIN: 11593622), currently an Independent Director on the Board of Wuxi Biologics Limited, as an Additional Director (Non-Executive - Independent Director) of the Company with effect from June 15, 2026.

The approval of the members as required under Regulation 17(1A), (1C) and 25(2A) of Listing Regulations for the aforesaid appointment will be obtained within the stipulated timelines, through a postal ballot and e-voting.

- III. Mr. Satyanarayana Murthy Chavali, Independent Director of the Company has tendered his resignation as an Independent Director in the Company due to the possibility of a potential conflict of interest that may arise in the future. The Company of which Mr. Satyanarayana Murthy is a Promoter and Director proposes entering a business segment that may be similar to or overlap with the business activities that Gland Pharma Limited is contemplating entering in the future.

Mr. Satyanarayana Murthy confirmed that there are no other material reasons for his resignation apart from the reason stated above.

Regd. Office:
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:
Plot No. 11 & 84, TSIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999



The resignation was accepted with effect from the close of the business hours on June 15, 2026.

Mr. C.S.N. Murthy has been associated with the Company since November 20, 2018 and has been a strong force in heralding the Company in achieving excellence. The Board of Directors of the Company and the entire Gland Pharma family places on record their deep sense of appreciation for the long-standing leadership and contribution of Mr. C.S.N. Murthy towards the success of the Company.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 with respect I, II & III are given in **Annexure-A** and a copy of resignation letter along with detailed reasons thereof of Mr. C.S.N. Murthy are provided in **Annexure-B** enclosed herewith.

- IV. In compliance with the provisions of Regulation 24 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and consequent to the resignation of Mr. C.S.N. Murthy as an Independent Director of the Company, Mr. Essaji Goolam Vahanvati, DIN: 00157299, Independent Director of the Company, has been appointed as a Director on the Board of Gland Pharma International Pte. Ltd (Material Subsidiary of the Company) with effect from June 15, 2026.

Accordingly, the list of the Board of Directors of Gland Pharma International Pte. Ltd after reconstitution is enclosed herewith as **Annexure - C**.

- V. With reference to the aforesaid changes among the Board of Directors of the Company, the Committees of the Board have been realigned with effect from June 15, 2026 in compliance with the Listing Regulations.

The details of all the Committees of the Board as of June 15, 2026 along with changes made are given in **Annexure - D** enclosed herewith.

The Board meeting was commenced at 15:00 Hrs. IST and was concluded at 15:50 Hrs. IST

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer**

Encl: As above

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Details of Mr. Udo Jahannes Vetter

SI. No	Particulars	Remarks
1	Reason for change	Mr. Udo Jahannes Vetter, DIN: 00707474, who has been appointed as Independent Director of the Company for a period of five years with effect from July 21, 2021 to July 20, 2026 by the shareholders of the Company, in terms of Section 149 of the Companies Act, 2013; be and is hereby reappointed as an Independent Director of the Company for a second term of five consecutive years, with effect from July 21, 2026 till July 20, 2031.
2	Date of Change	Effective from July 21, 2026
3	Brief profile	<p>Mr. Udo J. Vetter earned his degree in Clinical Pharmacy from the University of Washington and subsequently worked for five years as a Manufacturing Pharmacist at Schering-Plough Corp. (now Merck & Co., Inc.), where he was responsible for establishing production facilities in Puerto Rico.</p> <p>From 1985 to 1988, Mr. Udo J. Vetter served as Vice President, Licensing & Production, at Martec Inc., a generic pharmaceutical manufacturer based in Kansas City, Missouri, USA. During the late 1980s, he was President of the start-up company Vetter Pharma-Turm Inc. in Pennsylvania, USA.</p> <p>From 1987 to 1991, Mr. Udo J. Vetter served as Managing Director of Vetter Pharma. He subsequently held the position of Managing Director of Vetter Inject GmbH & Co. KG, the technical arm of the Vetter Group, from 1989 to 2003.</p> <p>Between 1999 and 2004, he was a member of the Executive Committee of Vetter Pharma Corporation. Since 1999, Mr. Udo J. Vetter has been a member of the Board of</p>

		<p>Directors of Vetter Pharma Corporation and has served as its Chairman since 2008.</p> <p>In 2004, Mr. Udo J. Vetter founded UV-Cap, an investment company focused on supporting mid-sized B2B businesses in the life sciences sector and acting as a long-term strategic partner to high-potential enterprises. He continues to serve as Managing Director of UV-Cap.</p> <p>Mr. Udo J. Vetter currently serves as Chairman of the ITM Group, Germany. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and of the Global Pharmaceutical Manufacturing Leadership Forum (GPMLF). Following six years as President of the European Family Businesses (EFB) Association, he now serves as Vice-President of the organization.</p> <p>In addition, Mr. Udo J. Vetter served as Chairman of the University Council of the University of Albstadt-Sigmaringen until 2018 and was awarded the title of Honorary Senator in recognition of his contributions to the institution.</p>
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

Details of Mr. William Robert Keller

SI. No	Particulars	Remarks
1	Reason for change	Mr. William Robert Keller, DIN: 11593622 was appointed as an Additional Director (Non-Executive Independent Director) of the Company.
2	Date of Change	Effective from June 15, 2026
3	Brief profile	<p>Mr. William Robert Keller, aged 78, is currently an Independent Director of Wuxi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO) in Biologics, listed on Hongkong Stock Exchange. He is also an Independent Director on Hua Medicine, a Company listed on Hongkong Stock Exchange.</p> <p>During August, 2020 to August, 2025; Mr. William Keller was a Director of Cathay Biotech Inc, which is listed on Shanghai Stock exchange. He was the Chairman of Coland Pharmaceutical Co. Ltd (earlier listed on Taiwan Stock Exchange) for ten years till November, 2020.</p> <p>Earlier, from December, 2009 to May, 2015; he was an Independent Director on the Board of Alexion Pharmaceuticals Inc., a Nasdaq listed entity. For seven years, till December, 2014 Mr. William Keller was also an Independent Director of Taigen Biopharmaceutical Holding Limited, a Taiwan Stock Exchange listed company.</p> <p>Mr. William Keller has more than 40 years of experience in managing operations in South America and Asia, particularly in pharmaceutical and biotechnology sectors. Mr. Keller spent almost three decades in different management positions with Roche in South America and Asia. From 1990 to 1994, he served as the Managing Director of Roche Hong Kong with regional responsibilities, and subsequently from 1994 to 2003, he was the General Manager for Roche China Holding, and Shanghai Roche Pharmaceutical Ltd., where he established and built up the Roche business in China.</p> <p>In 2003, Mr. Keller founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry</p>

		<p>strategies for foreign biotech companies into the Chinese market and supporting biopharma start-up companies in Shanghai.</p> <p>During June, 1997 to December, 2013; Mr. Keller served as the Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment, advising and supporting foreign invested companies as a business advisor. From March, 2003 to June, 2014; Mr. Keller was appointed as Deputy General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd, focusing on pharmaceutical and biotechnological industry development. From March, 2003 to December, 2013, he served as a Senior Consultant of the Shanghai Foreign Investment Development Board, providing advice regarding foreign investment development. From May, 2007 to April, 2010; Mr. Keller served as the Chairman of HBM Biomed China Partners Ltd., overseeing investments in biotechnology companies.</p> <p>Mr. Keller holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland, in July, 1972.</p>
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

**Details of Mr. Satyanarayana Murthy Chavali**

Sl. No	Particulars	Remarks
1	Reason for change	Mr. Satyanarayana Murthy Chavali, DIN: 00142138, Independent Director of the Company has tendered resignation to his directorship in the Company due to the possibility of a potential conflict of interest that may arise in the future. The Company of which Mr. Satyanarayana Murthy is a Promoter and Director proposes to enter a business segment that may be similar to or overlap with the business activities that Gland Pharma Limited has proposed to enter.
2	Date of Change	Effective from the close of business hours on June 15, 2026
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

15.06.2026

To

The Board of Directors

Gland Pharma Limited

Sy.No. 143-148, 150 & 151,

Near Gandimaisamma 'X' Roads,

D.P.Pally, Dundigal,

Medchal-Malkajgiri District

Hyderabad – 500 043

Subject: Resignation from the position of Independent Director

Dear Members of the Board,

I hereby tender my resignation from the position of Independent Director of the Company with effect from the close of business hours on 15th June, 2026.

This decision has been taken after careful consideration due to the possibility of a potential conflict of interest that may arise in the future. A company, of which I am a Promoter and Director proposes entering a business segment that may be similar to or overlap with the business activities that Gland Pharma is contemplating entering in the future.

In order to maintain the highest standards of corporate governance, transparency, and independence expected from an Independent Director, I believe it is appropriate to step down from my position.

I confirm that there are no other material reasons for my resignation apart from the reason stated above.

I would like to express my sincere gratitude to the Board and the Management, for the support and cooperation extended to me during my tenure. It has been a privilege to be associated with Gland, and I wish the Company continued success in all its future endeavours.

Kindly acknowledge receipt of this resignation and arrange to complete the necessary statutory filings and formalities in accordance with applicable laws and regulations.

Thank you.

Yours sincerely,



Chavali Satyanarayana Murthy

Independent Director

DIN: 00142138

murthy.csn@gmail.com

+91 9880297350



Annexure C

List of Board of Directors of Gland Pharma International Pte. Ltd, effective June 15, 2026

S. No	Name of the Director
1	Mr. Srinivas Sadu
2	Mr. Essaji Goolam Vahanvati
3	Mr. Wu Rong (Mr. Raymond Wu)
4	Ms. Liao Rong (Ms. Carol Rong)

Annexure D

Composition of Committees of Board of Directors as on June 15, 2026

Name of the Committee	Name of the Committee members and Category (Chairperson/Executive/non-executive/Independent/Nominee)	Remarks (changes made)
Audit Committee	a) Essaji Goolam Vahanvati - Chairman (of the Committee) & Independent Director b) William Robert Keller- Independent Director c) Udo Johannes Vetter- Independent Director	Mr. William Keller was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Essaji Vahanvati has been appointed as the Chairman of the Committee.
Nomination & Remuneration Committee	a) Udo Johannes Vetter - Chairman (of the Committee) & Independent Director b) Essaji Goolam Vahanvati- Independent Director c) William Robert Keller- Independent Director d) Ms. Wei Huang – Non-Executive Director	Mr. William Keller was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Udo J Vetter has been appointed as the Chairman of the Committee.
Risk Management Committee	a) Naina Lal Kidwai- Chairperson (of the Committee) & Independent Director b) Srinivas Sadu- Executive Chairman c) Dr. Jia Ai Zhang - Non- Executive Director d) Ravi Shekhar Mitra- Chief Financial Officer	No Change
Stakeholders' Relationship Committee & Share Transfer Committee	a) Udo J Vetter - Chairman (of the Committee) & Independent Director b) Srinivas Sadu- Executive Chairman & CEO c) Wenjie Zhang- Non- Executive Director	Mr. Udo J Vetter was appointed as the Chairman of the Committee replacing Mr. C.S.N. Murthy
Corporate Social Responsibility Committee	a) Srinivas Sadu- Chairman (of the Committee) & Executive Chairman b) Essaji Goolam Vahanvati- Independent Director c) Dr. Jia Ai Zhang- Non-Executive Director	No Change
ESOP Compensation Committee	a) Udo J Vetter- Chairman (of the Committee) & Independent Director b) Essaji Goolam Vahanvati- Independent Director c) Srinivas Sadu- Executive Chairman	Mr. Srinivas Sadu was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Udo J Vetter has been appointed as the Chairman of the Committee.